AKT3 (G171R)
Sign in to save this workspaceAKT3 · Variant type: point · HGVS: p.G171R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Capivasertib | 96.9% | 3.1% | 96.48 |
| 2 | Selpercatinib | 29.3% | 70.7% | 96.72 |
| 3 | Deucravacitinib | 25.8% | 74.3% | 98.99 |
| 4 | Tivozanib | 21.1% | 78.9% | 92.42 |
| 5 | Sunitinib | 19.0% | 81.0% | 91.73 |
| 6 | Erdafitinib | 17.9% | 82.1% | 95.71 |
| 7 | Abrocitinib | 12.5% | 87.5% | 99.50 |
| 8 | Ruxolitinib | 12.0% | 88.0% | 98.25 |
| 9 | Brigatinib | 10.8% | 89.2% | 82.96 |
| 10 | Umbralisib | 9.9% | 90.1% | 98.74 |
| 11 | Encorafenib | 9.3% | 90.7% | 98.50 |
| 12 | Mitapivat | 8.1% | 91.9% | 100.00 |
| 13 | Regorafenib | 7.0% | 93.0% | 95.99 |
| 14 | Repotrectinib | 6.5% | 93.5% | 84.21 |
| 15 | Quizartinib | 6.2% | 93.8% | 99.50 |
| 16 | Cobimetinib | 6.2% | 93.8% | 100.00 |
| 17 | Leniolisib | 6.1% | 93.9% | 100.00 |
| 18 | Palbociclib | 5.7% | 94.3% | 98.75 |
| 19 | Infigratinib | 5.5% | 94.5% | 98.24 |
| 20 | Paxalisib | 5.0% | 95.0% | 99.75 |
| 21 | Canertinib | 4.6% | 95.4% | 96.49 |
| 22 | Binimetinib | 4.4% | 95.6% | 100.00 |
| 23 | Pacritinib | 4.3% | 95.7% | 88.64 |
| 24 | Abemaciclib | 4.2% | 95.8% | 91.48 |
| 25 | Apatinib | 4.2% | 95.8% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Capivasertib | 96.9% | 98.5% | -1.6% |
| Selpercatinib | 29.3% | — | — |
| Deucravacitinib | 25.8% | — | — |
| Tivozanib | 21.1% | — | — |
| Sunitinib | 19.0% | 9.6% | +9.4% |
| Erdafitinib | 17.9% | — | — |
| Abrocitinib | 12.5% | — | — |
| Ruxolitinib | 12.0% | — | — |
| Brigatinib | 10.8% | — | — |
| Umbralisib | 9.9% | 25.9% | -16.1% |
| Encorafenib | 9.3% | — | — |
| Mitapivat | 8.1% | — | — |
| Regorafenib | 7.0% | — | — |
| Repotrectinib | 6.5% | — | — |
| Quizartinib | 6.2% | — | — |
| Cobimetinib | 6.2% | — | — |
| Leniolisib | 6.1% | 27.4% | -21.3% |
| Palbociclib | 5.7% | — | — |
| Infigratinib | 5.5% | 13.5% | -8.1% |
| Paxalisib | 5.0% | 11.4% | -6.4% |
| Canertinib | 4.6% | — | — |
| Binimetinib | 4.4% | — | — |
| Pacritinib | 4.3% | 9.6% | -5.2% |
| Abemaciclib | 4.2% | — | — |
| Apatinib | 4.2% | 13.3% | -9.1% |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| glioma_central_nervous_system | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms